ClinicalTrials.gg
TerminatedNCT02618577NOAHUpdated Feb 6, 2025Results posted

Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes

A Phase 3 interventional study of Edoxaban and ASA in Atrial High Rate Episodes, sponsored by Atrial Fibrillation Network. Terminated at 18 sites in 18 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-02-06.

Sponsored by Atrial Fibrillation Network · Phase 3, Interventional, and Prevention

How we know

Why this study was terminated
following a recommendation from the data safety and monitoring board due to safety concerns and a tendency towards futility.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,608
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies testing edoxaban in Atrial Fibrillation — 5 open to participants now, 6 under way, 1 of them phase 3. edoxaban · Atrial Fibrillation.

Enrollment
4th of 29
2,608 · median 536
Started
2016
with 1 other
Phase 3
10 of 29
none open now
Registered
8th of 29
by date
Lead sponsor
1 of 29
Atrial Fibrillation Network

Among the 29 studies testing edoxaban in Atrial Fibrillation, this one is the 4th largest by enrollment, is one of 2 that started in 2016, is one of 10 in phase 3, and was the 8th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

5 of the 29 studies testing edoxaban in Atrial Fibrillation are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About edoxaban

edoxaban: first FDA approval 2015 (SAVAYSA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing edoxaban in Atrial Fibrillation, or all of them as a file.
02

Study summary

NOAH is an investigator-initiated, prospective, parallel-group, double-blind, randomised, multi-centre trial. The objective of the trial is to demonstrate that oral anticoagulation using the NOAC edoxaban is superior to current therapy to pre-vent stroke, systemic embolism, or cardiovascular death in patients with AHRE and at least two stroke risk factors but without AF. The trial will be conducted in several European countries.

Read the detailed description

Atrial fibrillation (AF) is a common cause of stroke, especially ischemic stroke. So far, all available data that demonstrate a beneficial effect of oral anticoagulation for stroke prevention have been collected in populations with AF documented by conventional ECG recordings. It is well established that a large proportion of AF episodes remain undiagnosed ("silent AF"), and many of these patients present with a stroke as the first clinical sign of AF. Earlier initiation of anticoagulation could prevent such events. Continuous monitoring of atrial rhythm by implanted devices could close this diagnostic gap. Pacemakers, defibrillators, and cardiac resynchronisation devices already provide automated algorithms alerting to the occurrence of highly organised atrial tachyarrhythmia episodes, also called "subclinical atrial fibrillation" or, more commonly, "atrial high rate episodes" (AHRE). Data from large prospectively followed patient cohorts demonstrated that stroke rate is increased in patients with AHRE. A sizeable portion of these patients develops clinically detected AF over time. In these patients, AHRE can be considered as an early manifestation of paroxysmal AF. A few AHRE patients do not develop clinically overt AF, and the absolute stroke rates are lower in patients with AHRE when compared to stroke rates in patients with clinically diagnosed AF. In light of the bleeding complications associated with oral anticoagulant therapy, there is thus uncertainty about the optimal antithrombotic therapy in patients with AHREs.

The Non-vitamin K antagonist Oral anticoagulants (NOACs) provide similar or slightly better stroke prevention, and appear slightly safer compared to vitamin K antagonists (VKAs). In addition, no individual therapy adjustment of NOACs has to be performed. Edoxaban, a newly introduced NOAC, at a dose regime of 60 mg once daily (OD) has a favourable profile compared to dose-adjusted VKA therapy: In the ENGAGE-TIMI 48 trial, edoxaban prevented strokes at least as effectively as VKA therapy but caused less major bleeding events than VKA therapy.

03

Conditions studied

  • Atrial High Rate Episodes

Browse trials for

Keywords

  • Anticoagulation
  • Atrial High Rate Episodes
  • Atrial Fibrillation
  • VKA
  • NOAC
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pacemaker, defibrillator or insertable cardiac monitor implanted for any reason with feature of detection of AHRE, implanted at least 2 months prior to randomisation
  • AHRE detection feature activated for adequate detection of AHRE (refer to Appendix XIII)
  • AHRE (≥ 170 bpm atrial rate and ≥ 6 min duration) documented by the implanted device via its atrial lead and stored digitally. Any AHRE episode recorded is potentially eligible, but AHRE episodes detected in the first 2 months after implantation of a new device involving placement or repositioning of atrial electrodes are not eligible. AHRE episodes recorded in the first two months after a simple "box change" operation, i.e. exchange of a pacemaker or defibrillator device without exchange or repositioning of atrial electrodes, are eligible
  • Provision of signed
  • Age ≥ 65 years

In addition, at least one of the following cardiovascular conditions leading to a modified CHA2DS2VASc score of 2 or more:

  • Age ≥ 75 years
  • Heart failure (clinically overt or \< 45%)
  • Arterial hypertension (chronic treatment for hypertension, estimated need for continuous antihyper-tensive therapy or resting blood pressure > 145/90 mmHg)
  • Diabetes mellitus
  • Prior stroke or (TIA)
  • Vascular disease (previous myocardial infarction, peripheral, carotid/cerebral, or aortic plaques on transesophageal echocardiogram [TEE])
  • Provision of signed informed consent

Exclusion criteria

Exclusion Criteria:

  • Any disease that limits to less than 1 year
  • Participation in another controlled clinical trial, either within the past two months or still ongoing
  • Previous participation in the present trial NOAH - AFNET 6
  • Drug abuse or clinically manifest alcohol abuse
  • Any history of overt AF or atrial flutter
  • Indication for oral anticoagulation (e.g. deep venous thrombosis)
  • for oral anticoagulation in general
  • Contraindication for edoxaban as stated in the current SmPC
  • Indication for long-term antiplatelet therapy other than acetylsalicylic acid or a need for treatment with any antiplatelet agent in addition to edoxaban, especially dual antiplatelet therapy (DAPT). Patients with a transient requirement for DAPT (e.g. after receiving a stent) will be eligible when the need for DAPT is no longer present
  • Acute coronary syndrome, coronary revascularisation (PCI or bypass surgery), or overt stroke within 30 days prior to randomisation
  • End stage renal disease ( (CrCl) \< 15 ml/min as calculated by the Cockcroft-Gault method)
  • All persons exempt from participation in a clinical trial by law
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
2,608 participants (actual)

Study arms

  • Experimental
    Edoxaban

    Edoxaban will be applied in NOAH at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics: Impaired renal function (CrCl 15-50 ml/min), or low body weight (≤60 kg), or patients receiving the glycoprotein-P inhibitors cyclosporin, dronedarone, erythromycin, or ketoconazole.

    Drug: Edoxaban

  • Active comparator
    ASA or Placebo

    Either one tablet of ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg or one placebo tablet matching in colour, weight, form and size to ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg will be administered per day depending on the indication for use of antiplatelet therapy as assessed by the responsible investigator

    Drug: ASA

Interventions

  • Edoxaban will be applied at the therapeutic dose approved for stroke prevention in non-valvular AF

    Also known as: Lixiana, Savaysa

  • DrugAspirinStudies of AspirinAspirin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    ASA 100 mg tablets or Placebo, based on accepted indication for the latter, including peripheral or coronary artery disease, a prior myocardial infarction, or a prior stroke.

    Also known as: ASS

06

What researchers measure

Primary outcomes

  1. Composite of Stroke, Systemic Embolism, or Cardiovascular Death

    Time from randomisation to the first occurrence of stroke, systemic embolism, or cardiovascular death; incidence of first occurence of outcome measure.

    Time frame: 28 months

Secondary outcomes

  1. Components of the Primary Outcome, Stroke

    Time from randomisation to the first occurrence of ischemic stroke; incidence of first occurence of outcome measure.

    Time frame: 28 months

  2. Major Adverse Cardiac Events (MACEs: Cardiac Death, Myocardial Infarction, Acute Coronary Syndrome (ACS)

    PCI, CABG

    Time frame: 28 months

  3. All-cause Death

    All-cause death

    Time frame: 28 months

  4. Major Bleeding Events

    according to the International Society on Thrombosis and Haemostasis (ISTH) definitions

    Time frame: 28 months

  5. Quality of Life Changes at 12 and 24 Months Compared to Baseline

    Adjusted mean change from baseline at 12 and 24 months of Quality of life as assessed by the EuroQol Group 5-Dimension 5-Level questionnaire (EQ-5D-5L): The resulting score of the UK index ranges from 1 (for the best state) to - 0.285 (for the worst state), with 5.1% of the states valued as worse than dead. EQ5D- VAS: visual-analogue scale (0 worst to 100 best). Subscales of the UK index score were combined by adding up EQ-5D-5L index values with STATA using the English (ENG) Devlin value set, Version 1.1 (Updated 01/12/2020). Karnofsky Performance Scale is an 11-point scale from 0 to 100 (0 worst to 100 best).

    Time frame: Baseline, 12 months and 24 months.

  6. Patient Satisfaction at 12 and 24 Months Compared to Baseline

    Adjusted change from baseline at 12 and 24 months measured by the Perception of Anticoagulant Treatment Questionnaire: For convenience score, a 0 - 100 scale; for satisfaction score a 0 - 100 scale; for both scores, the higher the score, the higher the convenience/satisfaction.

    Time frame: Baseline, 12 months and 24 months.

  7. Cost Effectiveness and Health Resource Utilisation

    estimated by quantification of relevant events, interventions, nights spent in hospital and cardiovascular therapies

    Time frame: 28 months

  8. Autonomy Status

    Autonomy status only in patients with stroke during study participation, assessed at 24 month by modified Rankin scale. (Score ranges from 1 to 8, a higher score indicates a higher grade of disability)

    Time frame: Baseline and 24 months

  9. Components of the Primary Outcome, Systemic Embolism

    Time from randomisation to the first occurrence of systemic embolism; incidence of first occurence of outcome measure.

    Time frame: 28 months

  10. Components of the Primary Outcome, Cardiovascular Death

    Time from randomisation to the first occurrence of cardiovascular death; incidence of first occurence of outcome measure.

    Time frame: 28 months

07

Results

Posted Feb 6, 2025
Limitations and caveats
The trial does not have sufficient power to detect or rule out a small beneficial effect of oral anticoagulation on the prevention of stroke. The generalizability of these findings with edoxaban to other NOACs is not known.

Participant flow

Participant flow — Overall Study
MilestoneEdoxabanASA or Placebo
Started13061302
Completed500472
Not completed806830

Outcome measures

PrimaryComposite of Stroke, Systemic Embolism, or Cardiovascular Death

Time from randomisation to the first occurrence of stroke, systemic embolism, or cardiovascular death; incidence of first occurence of outcome measure.

Time frame:
28 months
Reported as:
Number · number of new events per 100 pat.-years
Composite of Stroke, Systemic Embolism, or Cardiovascular Death
number of new events per 100 pat.-yearsEdoxabanASA or Placebo
Composite of Stroke, Systemic Embolism, or Cardiovascular Death3.34.0
Statistical analysis
  • Edoxaban vs ASA or Placebo · Cause-spec. Cox Proport. Hazard model · p = 0.15 · Adjusted cause-specific hazard ratio: 0.81 · 95% CI 0.6 to 1.08
SecondaryComponents of the Primary Outcome, Stroke

Time from randomisation to the first occurrence of ischemic stroke; incidence of first occurence of outcome measure.

Time frame:
28 months
Reported as:
Number · number of new events per 100 pat.-years
Components of the Primary Outcome, Stroke
number of new events per 100 pat.-yearsEdoxabanASA or Placebo
Components of the Primary Outcome, Stroke0.91.1
Statistical analysis
  • Edoxaban vs ASA or Placebo · Adjusted cause-specific hazard ratio: 0.79 · 95% CI 0.45 to 1.39
SecondaryMajor Adverse Cardiac Events (MACEs: Cardiac Death, Myocardial Infarction, Acute Coronary Syndrome (ACS)

PCI, CABG

Time frame:
28 months
Reported as:
Number · number of new events per 100 pat.-years
Major Adverse Cardiac Events (MACEs: Cardiac Death, Myocardial Infarction, Acute Coronary Syndrome (ACS)
number of new events per 100 pat.-yearsEdoxabanASA or Placebo
Major Adverse Cardiac Events (MACEs: Cardiac Death, Myocardial Infarction, Acute Coronary Syndrome (ACS)3.64.1
Statistical analysis
  • Edoxaban vs ASA or Placebo · Adjusted cause-specific hazard ratio: 0.89 · 95% CI 0.67 to 1.18
SecondaryAll-cause Death

All-cause death

Time frame:
28 months
Reported as:
Number · number of new events per 100 pat.-years
All-cause Death
number of new events per 100 pat.-yearsEdoxabanASA or Placebo
All-cause Death4.33.7
Statistical analysis
  • Edoxaban vs ASA or Placebo · Cause-spec. Cox Proport. Hazard model · p = 0.28 · Adjusted cause-specific hazard ratio: 1.16 · 95% CI 0.88 to 1.53
SecondaryMajor Bleeding Events

according to the International Society on Thrombosis and Haemostasis (ISTH) definitions

Time frame:
28 months
Reported as:
Number · number of new events per 100 pat.-years
Major Bleeding Events
number of new events per 100 pat.-yearsEdoxabanASA or Placebo
Major Bleeding Events2.11.0
Statistical analysis
  • Edoxaban vs ASA or Placebo · Cause-spec. Cox Proport. Hazard model · p = 0.002 · Adjusted cause-specific hazard ratio: 2.1 · 95% CI 1.3 to 3.38
SecondaryQuality of Life Changes at 12 and 24 Months Compared to Baseline

Adjusted mean change from baseline at 12 and 24 months of Quality of life as assessed by the EuroQol Group 5-Dimension 5-Level questionnaire (EQ-5D-5L): The resulting score of the UK index ranges from 1 (for the best state) to - 0.285 (for the worst state), with 5.1% of the states valued as worse than dead. EQ5D- VAS: visual-analogue scale (0 worst to 100 best). Subscales of the UK index score were combined by adding up EQ-5D-5L index values with STATA using the English (ENG) Devlin value set, Version 1.1 (Updated 01/12/2020). Karnofsky Performance Scale is an 11-point scale from 0 to 100 (0 worst to 100 best).

Time frame:
Baseline, 12 months and 24 months.
Reported as:
Number · adjusted mean change from baseline
Quality of Life Changes at 12 and 24 Months Compared to Baseline
adjusted mean change from baselineEdoxabanASA or Placebo
EQ-5D-5L UK Index to FU12-0.01 (-0.03 to 0)-0.01 (-0.02 to 0.01)
EQ-5D-5L UK Index to FU24-0.04 (-0.05 to -0.02)-0.03 (-0.05 to -0.02)
EQ-5D-5L VAS to FU12-0.75 (-2.08 to 0.57)-0.71 (-2.06 to 0.64)
EQ-5D-5L VAS to FU24-1.72 (-3.18 to -0.27)-1.68 (-3.16 to 0.20)
Karnofsky score to FU12-1.14 (-1.98 to -0.31)-1.41 (-2.26 to -0.57)
Karnofsky score to FU24-2.28 (-3.23 to -1.33)-2.55 (-3.50 to -1.59)
Statistical analysis
  • Edoxaban vs ASA or Placebo · Mean difference (final values): -0.01 · 95% CI -0.02 to 0.01Estimation Parameter: baseline adjusted trial-group specific effect estimates (mean difference)
  • Edoxaban vs ASA or Placebo · Mean difference (final values): -0.04 · 95% CI -1.46 to 1.38Estimation Parameter: baseline adjusted trial-group specific effect estimates (mean difference)
  • Edoxaban vs ASA or Placebo · Mean difference (final values): 0.27 · 95% CI -0.56 to 1.09Estimation Parameter: baseline adjusted trial-group specific effect estimates (mean difference)
SecondaryPatient Satisfaction at 12 and 24 Months Compared to Baseline

Adjusted change from baseline at 12 and 24 months measured by the Perception of Anticoagulant Treatment Questionnaire: For convenience score, a 0 - 100 scale; for satisfaction score a 0 - 100 scale; for both scores, the higher the score, the higher the convenience/satisfaction.

Time frame:
Baseline, 12 months and 24 months.
Reported as:
Number · scores on a scale (with 95% Confidence I
Patient Satisfaction at 12 and 24 Months Compared to Baseline
scores on a scale (with 95% Confidence IEdoxabanASA or Placebo
PACT-Q convenience to FU120.84 (-0.26 to 1.93)0.96 (-0.14 to 2.05)
PACT-Q convenience to FU241.35 (0.2 to 2.49)1.47 (0.32 to 2.61)
PACT-Q satisfaction to FU122.97 (1.36 to 4.57)4.01 (2.39 to 5.62)
PACT-Q satisfaction to FU243.80 (2.12 to 5.48)4.84 (3.15 to 6.52)
Statistical analysis
  • Edoxaban vs ASA or Placebo · Mean difference (final values): -0.12 · 95% CI -1.12 to 0.87Estimation Parameter: baseline adjusted trial-group specific effect estimates (mean difference)
  • Edoxaban vs ASA or Placebo · Mean difference (final values): -1.04 · 95% CI -2.60 to 0.52Estimation Parameter: baseline adjusted trial-group specific effect estimates (mean difference)
SecondaryCost Effectiveness and Health Resource Utilisation

estimated by quantification of relevant events, interventions, nights spent in hospital and cardiovascular therapies

Time frame:
28 months

Results for this outcome have not been posted.

SecondaryAutonomy Status

Autonomy status only in patients with stroke during study participation, assessed at 24 month by modified Rankin scale. (Score ranges from 1 to 8, a higher score indicates a higher grade of disability)

Time frame:
Baseline and 24 months
Reported as:
Median · Scores on a scale
Autonomy Status
Scores on a scaleEdoxabanASA or Placebo
Autonomy Status3.0 (2.0 to 3.0)2.5 (2.0 to 3.0)
SecondaryComponents of the Primary Outcome, Systemic Embolism

Time from randomisation to the first occurrence of systemic embolism; incidence of first occurence of outcome measure.

Time frame:
28 months
Reported as:
Number · number of new events per 100 pat.-years
Components of the Primary Outcome, Systemic Embolism
number of new events per 100 pat.-yearsEdoxabanASA or Placebo
Components of the Primary Outcome, Systemic Embolism0.51.1
Statistical analysis
  • Edoxaban vs ASA or Placebo · Adjusted cause-specific hazard ratio: 0.51 · 95% CI 0.27 to 0.96
SecondaryComponents of the Primary Outcome, Cardiovascular Death

Time from randomisation to the first occurrence of cardiovascular death; incidence of first occurence of outcome measure.

Time frame:
28 months
Reported as:
Number · number of new events per 100 pat.-years
Components of the Primary Outcome, Cardiovascular Death
number of new events per 100 pat.-yearsEdoxabanASA or Placebo
Components of the Primary Outcome, Cardiovascular Death2.02.2
Statistical analysis
  • Edoxaban vs ASA or Placebo · Adjusted cause-specific hazard ratio: 0.90 · 95% CI 0.62 to 1.31

Adverse events

Collected over (S)AEs were collected during a median follow-up time of 21 months after the baseline visit for all patients until the trial was terminated, i.e. (S)AEs were collected through study completion. (S)AEs were collected on a 6 monthly basis after baseline visit. After the announcement of early termination of the trial due to safety reasons and futility, a final visit was conducted within 3 months for all active patients including a final (Serious) Adverse Event assessment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Edoxaban142/1,306 (10.9%)498/1,306 (38.1%)718/1,306 (55%)
ASA or Placebo125/1,302 (9.6%)467/1,302 (35.9%)662/1,302 (50.8%)
Most frequent serious events
Showing 10 of 738
Most frequent serious events
EventEdoxabanASA or Placebo
DeathGeneral disorders103/130687/1302
Viral test negativeInvestigations95/130693/1302
Cardiac failureCardiac disorders93/130690/1302
PneumoniaInfections and infestations58/130656/1302
TransfusionSurgical and medical procedures58/130628/1302
Cardiac pacemaker replacementSurgical and medical procedures38/130657/1302
Endoscopy upper gastrointestinal tractInvestigations54/130623/1302
Gastrointestinal haemorrhageGastrointestinal disorders50/130619/1302
AnaemiaBlood and lymphatic system disorders44/130616/1302
Diagnostic procedureInvestigations40/130616/1302
Most frequent other events
Showing 10 of 594
Most frequent other events
EventEdoxabanASA or Placebo
Coronavirus test positiveInvestigations48/130630/1302
EpistaxisRespiratory, thoracic and mediastinal disorders48/130621/1302
DizzinessNervous system disorders47/130646/1302
DyspnoeaRespiratory, thoracic and mediastinal disorders43/130642/1302
Cardiac pacemaker replacementSurgical and medical procedures36/130639/1302
FallInjury, poisoning and procedural complications32/130631/1302
HaematuriaRenal and urinary disorders31/13068/1302
ArthralgiaMusculoskeletal and connective tissue disorders18/130624/1302
NauseaGastrointestinal disorders21/130611/1302
HaematomaVascular disorders21/130617/1302

Baseline characteristics

Age, Continuous
Age, Continuous(years)EdoxabanASA or PlaceboTotal
Mean77.4 ± 6.577.5 ± 6.877.5 ± 6.7
Sex: Female, Male
Sex: Female, Male(Participants)EdoxabanASA or PlaceboTotal
Female469478947
Male8017861587
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)EdoxabanASA or PlaceboTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)EdoxabanASA or PlaceboTotal
Romania7714
Hungary353570
Czechia6612
Ukraine179172351
United Kingdom7680156
Portugal131225
Spain176177353
Greece437
Austria108113221
Netherlands222850
Sweden9716
Belgium15823
Poland137135272
Denmark11718
Italy8276158
Bulgaria91221
France414182
Germany340345685
08

Study locations

18 sites
  • Several Sites
    Multiple Locations, Austria
  • Several Sites
    Multiple Locations, Belgium
  • Several
    Multiple Locations, Bulgaria
  • Several
    Multiple Locations, Czechia
  • Several
    Multiple Locations, Denmark
  • Several
    Multiple Locations, France
  • Several Sites
    Multiple Locations, Germany
  • Several
    Multiple Locations, Greece
  • Several
    Multiple Locations, Hungary
  • Several
    Multiple Locations, Italy
  • Several
    Multiple Locations, Netherlands
  • Several
    Multiple Locations, Poland
  • Several
    Multiple Locations, Portugal
  • Several
    Multiple Locations, Romania
  • Several
    Multiple Locations, Spain
  • Several
    Multiple Locations, Sweden
  • Several
    Multiple Locations, Ukraine
  • Several
    Multiple Locations, United Kingdom
09

References and documents

Publications

  • Bertaglia E, Blank B, Blomstrom-Lundqvist C, Brandes A, Cabanelas N, Dan GA, Dichtl W, Goette A, de Groot JR, Lubinski A, Marijon E, Merkely B, Mont L, Piorkowski C, Sarkozy A, Sulke N, Vardas P, Velchev V, Wichterle D, Kirchhof P. Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence. Europace. 2019 Oct 1;21(10):1459-1467. doi: 10.1093/europace/euz172. PubMed 31377792 ↗
  • Kirchhof P, Blank BF, Calvert M, Camm AJ, Chlouverakis G, Diener HC, Goette A, Huening A, Lip GYH, Simantirakis E, Vardas P. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. Am Heart J. 2017 Aug;190:12-18. doi: 10.1016/j.ahj.2017.04.015. Epub 2017 May 3. PubMed 28760205 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2016 to primary completion in Dec 2022, 82 months.

Results were first posted in Feb 2025, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2015
First posted
Dec 1, 2015
StartActual
Feb 2016
Primary completionActual
Dec 31, 2022
CompletionActual
Dec 31, 2022
Results first posted
Feb 6, 2025
Last update
Feb 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02618577
Lead sponsor
Atrial Fibrillation Network
Collaborators
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
Responsible party
Sponsor
First posted
Dec 1, 2015
Start date
Feb 2016
Primary completion
Dec 31, 2022
Completion
Dec 31, 2022
Results posted
Feb 6, 2025
Last update
Feb 6, 2025

Study contacts

Paulus Kirchhof, Prof. Dr.
principal investigator · University Clinic of Hamburg-Eppendorf, Hamburg, Germany

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Edoxaban

Start the discussion